Successful Drug Launches
The patterns behind launches that exceed forecast.
What the most successful pharma launches did differently — patient identification, HCP enablement, access pre-positioning and post-launch RWE.
"What launch patterns should we adopt — and which mistakes should we avoid?"
Successful launches share four traits: precise patient identification, frictionless HCP enablement, access pre-positioning, and aggressive post-launch RWE programs.
The most successful pharma launches share four traits — pre-positioned access, AI-based patient identification, friction-free HCP enablement and aggressive post-launch RWE. Teams that build all four into the launch playbook consistently exceed forecast.
What we’re seeing in the data.
Pre-launch access is the make-or-break
Late-stage access work outperforms post-launch scrambles.
Patient identification scales adoption
AI-based patient finding accelerates launch curves.
HCP friction is the silent killer
Complex prior auth and admin friction blunt strong clinical profiles.
How to think about it.
-
01
Pre-position access
Payer dossiers, MEAs, pricing.
-
02
Build patient finding
AI eligibility, RWE.
-
03
De-friction HCP workflow
PA, admin, support.
-
04
Sustain with RWE
Post-launch evidence programs.
What separates a good answer from a defensible one.
Patterns differ by geo.
New TAs require education.
Combo launches harder.
Where the signal comes from.
Common questions.
#1 differentiator?
Pre-launch access work — by a wide margin.
How early to start?
18–24 months pre-launch.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist